SignalDailyGlobal signals. Global context.

Market Incident

Public · Developing

AI compiled from Infoway · 4 analyzed stories

BEAM: Two patients at 40 mg reached 15 hours fasting and stopped starch supplementation

BEAM-301 data showed glucose-restoration signals, with 2 of 3 patients at 40 mg reaching the 15-hour fasting maximum and stopping starch supplementation. The BEAM-304 platform showed consistent preclinical correction across three PKU variants.

Published:

Updated:

What happened

In the BEAM-301 trial, 2 of 3 patients at the 40 mg dose reached 15 hours of fasting and stopped cornstarch, a clinical proof of concept in GSD1a. Enrollment at the 60 mg dose is underway, and discussions with the FDA are planned on a potential efficient path forward.

Global impact / market context

This is an early signal that the treatment may help patients fast longer without cornstarch, which matters because it could point to a new option for people with this condition. It is small, early data, so it does not yet prove the treatment works or is safe for everyone.

What to watch

  1. Results from the 60 mg dose group: they will show whether higher doses produce stronger or more consistent effects.
  2. The planned FDA discussions: they will show whether regulators see a clear path forward for the program.
  3. The full safety profile across treated patients: it will show whether side effects remain consistent with similar therapies.

Affected assets

  • BEAM-301 (GSD1a gene-editing therapy program)

Evidence